















1146Transplanted CD341 Cell Dose Is Associated with
Long-Term Platelet Count Recovery following
Autologous Peripheral Blood Stem Cell Transplant
in Patients with Non-Hodgkin Lymphoma
or Multiple Myeloma
Patrick J. Stiff,1 Ivana Micallef,2 Auayporn P. Nademanee,3 Edward A. Stadtmauer,4
Richard T. Maziarz,5 Brian J. Bolwell,6 Gary Bridger,7 Sachin Marulkar,7
Frank J. Hsu,7 John F. DiPersio8Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with he-
matologic malignancies, yet the impact of transplanted CD341 cell dose on clinical outcomes is unresolved.
We conducted post hoc analyses of transplanted CD341 cell dose and hematopoietic recovery following
ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2
multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor
(G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the propor-
tion of patients who reached predetermined blood count thresholds were compared across 3 CD341 cell
dose levels: 2-4 106 cells/kg, 4-6 106 cells/kg, and.6 106 cells/kg, regardless of mobilization treatment.
Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear
trend was observed between transplanted CD341 cell dose and the proportion of patients with platelet
count .150  109/L at 100 days (P\ .001), 6 months (P 5 .026), and 12 months (P 5 .020) in patients
with NHL, and at 100 days in patients with MM (P5 .004). A linear trend was also observed between trans-
planted cell dose and the proportion of patients with platelet count.100 109/L at 100 days (P\.001) and
6 months (P5.023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL
patients requiring red blood cell transfusions (P 5 .006). Our analyses confirm previous findings that
transplanted CD341 cell dose may be associated with better long-term platelet recovery after ASCT.
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of patients with hematologic malignancies such as
non-Hodgkin lymphoma (NHL) and multiple mye-
loma (MM) [1-5]. This treatment strategy depends
on successful collection of sufficient hematopoietic
stem cells (HSCs). Approximately 20% of patients
with NHL or MM fail to mobilize the minimum
number of peripheral blood stem cells (PBSCs)
required for transplantation (generally accepted as
$2  106 CD341 cells/kg), with either cytokine
alone or cytokine plus chemotherapy [6-11]. In
patients with NHL, risk factors for poor HSC
mobilization include age, prior therapy, mobilization
regimen, and bone marrow involvement [6,9,12].
Factors that may affect mobilization in patients with
MM include older age, prior melphalan exposure,
extensive prior chemotherapy and/or radiotherapy,
.4-6 cycles of lenalidomide [13], and prolonged dis-
ease duration. Multiple mobilization attempts may
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with adverse implications including increased toxicity
or morbidity, delays in time to transplantation, and
higher cost of care. Accumulating evidence suggests
that among patients who are able to collect an ade-
quate number of CD341 cells and proceed to trans-
plantation, higher transplanted cell doses, $5  106
CD341 cells/kg, are associated with faster neutrophil
recovery [14-16], higher median platelet counts or
faster platelet recovery [16-18], improved disease-
free survival (DFS) and OS [19,20], and reduced
resource utilization and cost of care [21,22].
Plerixafor is a first-in-class small molecule drug that
is indicated for HSC mobilization. It acts by reversibly
inhibiting the binding of chemokine stromal cell-
derived factor-1a (SDF-1a) to its receptor CXCR4,
which is involved in the trafficking and homing of
HSCs to the bone marrow [23-25]. Plerixafor was
shown to mobilize CD341 hematopoietic progenitor
cells in healthy human subjects and patients with
NHL and MM [26,27]. Two randomized, double-
blind, placebo-controlled, phase 3 trials compared the
efficacy and safety of plerixafor plus granulocyte
colony-stimulating factor (G-CSF) versus placebo
plus G-CSF in mobilization of PBSCs for ASCT in pa-
tients with NHL (Study 3101) and MM (Study 3102).
Both studies showed that the combination of plerixafor
plus G-CSF was well tolerated and enabled signifi-
cantly more patients to collect the target number of
CD341 cells in fewer apheresis days, compared with
patients treated with placebo plus G-CSF [28,29].
To further validate the importance of CD341 cell
dose on hematopoietic recovery, we conducted post
hoc analyses of pooled disease-specific data from
studies 3101 and 3102, aiming to examine the rela-
tionship between transplanted CD341 cell dose and
posttransplantation recovery of neutrophils, platelets,
red blood cells, and lymphocytes; transfusion require-
ments; and survival, irrespective of the mobilization
regimen.PATIENTS AND METHODS
Study Design and Patient Population
This was a post hoc analysis of posttransplant out-
comes in patients with NHL or MM stratified by
transplanted CD341 cell dose from 2 phase 3, multi-
center, randomized, double-blind, placebo-controlled
studies comparing the safety and efficacy of plerixafor
plus G-CSF versus placebo plus G-CSF for the mobi-
lization of CD341 HSCs for autologous transplanta-
tion (Study 3101, NCT00103610, and Study 3102,
NCT00103662). For each study, regardless of the mo-
bilization regimen employed, transplantedCD341 cell
dose levelswere categorized as 2-4106 cells/kg, 4-6
106 cells/kg, and $6  106 cells/kg. These categorieswere chosen based on clinical judgment and to evaluate
the usefulness of a infusion cell dose beyond what most
consider optimum (5  106 CD34/kg). Patients who
underwent transplantation after a single mobilization
attempt and had data available with regard to the num-
ber of cells infused were included in this analysis; pa-
tients undergoing tandem transplantation and rescue
patients were excluded. There were 5 patients overall
(in 3101 and 3102) who were transfused with\2 
106 CD34 cells/kg. Because the cell dose transplanted
was very close to 2  106 cells/kg, these patients were
included in the 2-4 category.
Detailed information about the study design and
preliminary safety and efficacy outcomes were de-
scribed in previous publications [28,29]. Briefly,
patients with biopsy-confirmed diagnoses were eligi-
ble for enrollment in Study 3101 if they had NHL or
in Study 3102 if they had MM. Diagnoses were con-
firmed by biopsy prior to first mobilization. Other in-
clusion criteria common to the 2 studies included the
following: age 18 to 78 years, disease status of being
in first or second remission (complete or partial re-
sponse), eligibility for autologous HSCT, $4 weeks
since last cycle of chemotherapy, Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or
1, adequate blood cell counts, and adequate organ
function. Patients were excluded from the 2 studies if
they had a comorbid condition rendering them at
high risk for complications, failed previous HSC
collections or collection attempts, prior autologous
or allogeneic transplantation, received radiation ther-
apy to the pelvis, and anticipated posttransplantation
chemotherapy and/or radiation therapy below the
diaphragm. Exclusion criteria specific to Study 3101
included .20% bone marrow involvement and prior
radioimmunotherapy with ibritumomab tiuxetan
(Zevalin) or tositumomab (Bexxar); exclusion criteria
specific to Study 3102 included use of bone-seeking
radionuclides; .2 cycles of alkylating agent combina-
tions; and use of thalidomide, lenalidomide, dexa-
methasone, and/or bortezomib within 7 days prior to
first dose of G-CSF.Study Treatment
Randomized patients received G-CSF 10 mg/kg
subcutaneously daily in the morning for up to 8 days.
Beginning on day 4, patients received either plerixafor
0.24 mg/kg or placebo subcutaneously daily in the
evening for up to 4 days. Apheresis (3.0 blood volume
610%) began on the morning of day 5 and continued
daily for up to 4 days or until sufficient CD341 cells
were collected ($5  106 cells/kg for patients with
NHL and $6  106 cells/kg for patients with MM).
Apheresis products were processed and stored accord-
ing to local practice guidelines. Patients who failed to
collect either$0.8 106 cells/kg after 2 apheresis days
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tion to enter an open-label rescue procedure in which
they would receive a course of G-CSF and plerixafor as
described above.
Transplantation and Engraftment
Within 5 weeks of last apheresis, patients received
high-dose chemotherapy (with or without total-body
irradiation [TBI] for patients with MM) and under-
went transplantation using collected CD341 cells
according to local practice guidelines. G-CSF (5 mg/
kg) was started on day 5 or day 6 after stem cell trans-
plantation (SCT) and continued until absolute neutro-
phil count (ANC) was$0.5 109/L for 3 days or$1.0
 109/L for 1 day. Patients were followed for up to 12
months to monitor engraftment and graft durability.
The number of CD341 cells transplanted and blood
cell counts (ANC, lymphocyte, platelet, and red blood
cell [RBC]) at 100 days, 6 months, and 12 months was
determined by a central laboratory. Neutrophil en-
graftment was defined as neutrophil count $0.5 
109/L for 3 days or$1.0 109/L for 1 day. Platelet en-
graftment was defined as platelet count $20  109/L
without a transfusion for the preceding 7 days.
Maintenance therapy of any kind (chemotherapy
or radiation therapy) was not permitted after trans-
plantation for these patients, except to treat relapse
or if radiation therapy was low-dose, localized, and
necessary to treat lesions above the diaphragm (ie, me-
diastinum, supraclavicular). In the latter case, radiation
therapy was administered no earlier than day 100 and
completed by day 150.
Statistical Methods
The proportion of patients who had platelet levels
$150 109/L,$100 109/L, and$50 109/L; neu-
trophil counts$2.5 109/L; lymphocyte counts$0.5
 109/L; or hemoglobin level $13.8 g/dL (male) or
$12.1 g/dL (female) at 100 days and 6 and 12 months
were compared using Mantel-Haenszel chi-square test
to assess linear trends across 3 cell dose categories.
Continuous outcomes, number of transfusions, and
number of units transfused were compared between
the cell dose categories using Wilcoxon rank sum
test or Kruskal-Wallis test. Multiple comparisons
were tested using Bonferroni adjustment. A P value
#.05 was considered statistically significant, and all
analyses were performed using SAS version 8.2 (SAS
Institute Inc., Cary, NC).
RESULTS
HSC Mobilization and Transplantation
A total of 298 patients with NHL were enrolled in
Study 3101; of these, 217 were included in this analy-
sis: 52 patients who entered the rescue protocol and 29patients who did not proceed to transplantation were
excluded from this analysis [29,30]. A total of 302
patients with MM were enrolled in Study 3102; of
these, 221 patients were included in this analysis:
56 patients who underwent a tandem transplant,
7 patients who entered the rescue procedure, 17
patients who did not proceed to transplantation, and
1 patient who had missing information were
excluded from this analysis [28]. Patient disposition,
demographics, and baseline characteristics have been
described previously [28,29]. In both studies,
a significantly higher portion of patients who
received plerixafor plus G-CSF for mobilization were
able to proceed to transplantation directly, without
need for stem cell rescue procedure, than patients
who received G-CSF only (90.0% versus 55.4%,
respectively; P \ .001, in patients with NHL and
95.9% versus 88.3%, respectively; P 5 .018, in
patients with MM) (Table 1). The median numbers
of CD341 cells transplanted were also significantly
higher in patients who received plerixafor plus G-
CSF than in those who received G-CSF only for
both the NHL (P\ .001) and MM (P\ .001) groups
(Table 1).
Impact of CD341 Cell Dose on Neutrophil and
Platelet Engraftment
The short-term impact of CD341 cell dose, irre-
spective of the mobilization regimen, on times to neu-
trophil and platelet engraftment was evaluated in 217
patients with NHL and 221 patients with MM. In
NHL patients infused with 2-4  106 cells/kg (n 5
76), 4-6  106 cells/kg (n 5 75), and .6  106 cells/
kg (n 5 66), the median time to neutrophil engraft-
ment was 11 days, 10 days, and 10 days, respectively
(Table 2). Median time to platelet engraftment was
20 days in patients infused with 2-4  106 cells/kg (n
5 76) or 4-6 106 cells/kg (n5 75), and 19 days in pa-
tients infused with .6  106 cells/kg (n 5 66). The
median time to neutrophil engraftment in MM pa-
tients was 11 days irrespective of the infused cell
dose. The median time to platelet engraftment was
19 days in MM patients infused with 2-4  106 cells/
kg (n 5 75), and 18 days in MM patients infused
with 4-6  106 cells/kg (n 5 82) or .6  106 cells/
kg (n5 64). The impact of different CD341 cell doses
on time to neutrophil and platelet engraftment was not
statistically significant.Impact of CD341 Cell Dose on Long-Term
Platelet Recovery
The percentages of patients with platelet threshold
levels of 150 109/L, 100 109/L, or 50 109/Lwere
compared across all 3 CD341 cell dose categories,
regardless of mobilization treatment, at 100 days,
6 months, and 12 months posttransplantation. In
Table 1. CD34+ Cell Mobilization and Transplantation in
Patients with NHL and MM
Plerixafor + G-CSF Placebo + G-CSF P value
NHL (3101 Study)
No. of patients randomized 150 148
No. of patients proceeding to
transplantation (%)
135 (90.0) 82 (55.4) <.001
No. of CD34+ cells transplanted,
106 cells/kg
Mean ± SD 6.06 ± 2.98 4.09 ± 1.56 <.001
Median (range) 5.41 (1.79-17.6) 3.85 (1.98-8.70)
MM (3102 Study)
No. of patients randomized 148 154
No. of patients proceeding
to transplantation (%)
142 (95.9) 136 (88.3) .018
No. of CD34+ cells transplanted,
106 cells/kg
Mean ± SD 5.84 ± 2.64 4.37 ± 2.01 <.001
Median (range) 5.34 (1.90-16.7) 3.98 (1.80-16.9)
G-CSF indicates granulocyte-colony stimulating factor; MM, multiple
myeloma; NHL, non-Hodgkin lymphoma.
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observed between CD341 cell dose and percentage of
patients with a platelet threshold of 150 109/L at the
100-day (P \ .001), 6-month (P 5 .026), and 12-
month (P 5 .020) follow-ups (Table 3). In patients
with MM, a significant association was observed at
the 100-day follow-up (P 5 .004), but not at the 6-
and 12-month follow-ups (Table 3). In the 3101 study,
a significant linear association was observed between
CD341 cell dose and the percentage of patients with
a platelet threshold of 100  109/L at the 100-day
(P \ .001) and 6-month (P 5 .023) follow-ups, but
not at 12-month follow-up (Table 4). No significant
association was observed between cell dose and the
proportion of MM patients with platelet counts of
100  109/L for any follow-up time (Table 4). For
the 50  109/L platelet threshold, we did not observeTable 2. Time to Neutrophil and Platelet Engraftment in Patients
NHL (3101 Study)
2-4  106 Cells/kg (n 5 76)
Neutrophil engraftment, days
Mean ± SD 10.9 ± 2.5
Median (range) 11.0 (8.0–30.0)
Platelet engraftment, days
Mean ± SD 24.4 ± 12.3
Median (range) 20.0 (13.0–87.0)
MM (3102 study)
2-4  106 Cells/kg (n 5 75)
Neutrophil engraftment, days
Mean ± SD 11.9 ± 2.3
Median (range) 11.0 (9.0–25.0)
Platelet engraftment, days
Mean ± SD 21.5 ± 13.7
Median (range) 19.0 (1.0–95.0)
MM indicates multiple myeloma; NHL, non-Hodgkin lymphoma.a significant association between cell dose and propor-
tion ofMMorNHLpatients at any follow-up time pe-
riod (data not shown).
Impact of CD341 Cell Dose on Long-Term
Recovery of Lymphocytes, Neutrophils, and
RBC
After controlling for treatment groups, there were
no significant differences in mean lymphocyte, neutro-
phil, or hemoglobin recovery across all CD341 cell
doses at 100-day, 6-month, and 12-month follow-ups
in either patients with NHL or patients with MM
(data not shown).
Impact of CD341 Cell Dose on Transfusion
Requirement
The total number of platelet transfusions (defined
as transfusion of platelets at a given time regardless of
the reported number of units) in the 3101 and 3102
studies was 786 and 402, respectively. Across all 3
CD341 cell dose categories, there was no significant
linear association in the percentage of patients with
NHL or MM requiring platelet transfusion (Table 5).
There was a significant difference in the median num-
ber of platelet transfusions between the 2-4  106
cells/kg and .6  106 cells/kg cell dose categories
for NHL patients after adjusting for multiple compar-
isons (P 5 .03). There were no significant differences
in median number of platelet transfusions in MM
patients or median units of platelets transfused in
both NHL and MM patients across CD341 cell dose
categories.
The total number of RBC transfusions (defined as
transfusion of PRBC at a given time regardless of the
reported number of units) in the 3101 and 3102 studieswith NHL and MM
CD34+ Cell Dose Transfused
4-6  106 Cells/kg (n 5 75) >6  106 Cells/kg (n 5 66)
10.3 ± 1.5 10.1 ± 1.1
10.0 (8.0–18.0) 10.0 (8.0–13.0)
28.6 ± 44.8 23.2 ± 14.3
20.0 (9.0–384.0) 19.0 (9.0–103.0)
CD34+ Cell Dose Transfused
4-6  106 Cells/kg (n 5 82) >6  106 Cells/kg (n 5 64)
11.5 ± 1.4 10.6 ± 1.6
11.0 (9.0, 17.0) 11.0 (2.0–17.0)
19.1 ± 6.9 17.6 ± 8.5
18.0 (1.0, 40.0) 18.0 (1.0–57.0)
Table 3. Number and Percentage* of Patients Reaching Posttransplantation Platelet Threshold Level of 150  109/L
NHL (3101 study)
CD34+ Cell Dose
Time Posttransplantation 2-4  106 Cells/kg (n 5 76) 4-6  106 Cells/kg (n 5 75) $6  106 Cells/kg (n 5 66) P value†
100 days 28/58 (48.3%) 42/63 (66.7%) 45/55 (81.8%) <.001
6 months 31/55 (56.4%) 36/54 (66.7%) 42/55 (76.4%) .026
12 months 18/32 (56.3%) 21/26 (80.8%) 24/29 (82.8%) .020
MM (3102 Study)
CD34+ Cell Dose
Time Posttransplantation 2-4  106 Cells/kg (n 5 75) 4-6  106 Cells/kg (n 5 82) $6  106 Cells/kg (n 5 64) P value†
100 days 41/60 (68.3%) 57/63 (90.5%) 47/53 (88.7%) .004
6 months 48/61 (78.7%) 61/68 (89.7%) 51/58 (87.9%) .147
12 months 25/34 (73.5%) 33/40 (82.5%) 26/32 (81.3%) .435
MM indicates multiple myeloma; NHL, non-Hodgkin lymphoma.
*Percentages are based on the number of patients with available data at each follow-up time point.
†P value testing linear trend using Mantel-Haenszel chi-square test.
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ciation between higher CD341 cell dose and a lower
percentage of patients requiring RBC transfusion was
observed in patients with NHL (P 5 .006) (Table 5).
A similar association approaching a significant level
was also observed in patients with MM (P 5 .052).
No significant differences in median number of RBC
transfusions or median units of RBCs transfused
were found across CD341 cell dose categories.
Patient Survival and Posttransplantation
Myelodysplastic Syndrome (MDS)/Acute
Myeloid Leukemia (AML)
Patients were followed for at least 1 year after
transplantation. In patients withNHL, overall survival
(OS) rates at 1-year posttransplantation were 92.1%
(70/76), 85.3% (64/75), and 84.8% (56/66) in the
2-4 106, 4-6 106, and.6 106 cells/kg categories,Table 4. Number and Percentage* of Patients Reaching Posttransp
NHL (3101 study)
CD3
Time Posttransplantation 2-4  106 Cells/kg (n 5 76) 4-6  10
100 days 39/58 (67.2%) 57
6 months 44/55 (80.0%) 47
12 months 28/32 (87.5%) 23
MM (3102 Study)
CD3
Time Posttransplantation 2-4  106 Cells/kg (n 5 75) 4-6  10
100 days 54/60 (90.0%) 63
6 months 54/61 (88.5%) 64
12 months 32/34 (94.1%) 33
MM indicates multiple myeloma; NHL, non-Hodgkin lymphoma.
*Percentages are based on the number of patients with available data at each
†P value testing linear trend using Mantel-Haenszel chi-square test.respectively. In patients with MM, the 1-year survival
rates were 96.0% (72/75), 96.3% (79/82), and 92.2%
(59/64) in the 3 cell dose categories, respectively.
There was no significant difference in the 1-year sur-
vival rate among the 3 cell dose categories in both
NHL and MM studies. Among patients with NHL,
2 patients developed AML posttransplantation: 1 pa-
tient had genetic chromosome 6 mutation and devel-
oped pancytopenia that transformed into AML and
in the other patient development of AML (168 days
posttransplant) was assessed to be because of previous
exposure to liposomal doxorubicin and etoposide. The
2 patients received a cell dose of 5.04 106 and 2.74
106 cells/kg, respectively. Another NHL patient had
pre-existing chromosomal 5/7 abnormalities, which
was compatible with MDS. None of the patients
with MM developed MDS or AML during the 1-year
follow-up period.lantation Platelet Threshold Level of 100  109/L
4+ Cell Dose
6 Cells/kg (n 5 75) $6  106 Cells/kg (n 5 66) P value†
/63 (90.5%) 51/55 (92.7%) <.001
/54 (87.0%) 52/55 (94.6%) .023
/26 (88.5%) 27/29 (93.1%) .479
4+ Cell Dose
6 Cells/kg (n 5 82) $6  106 Cells/kg (n 5 64) P value†
/63 (100.0%) 51/53 (96.2%) .100
/68 (94.1%) 55/58 (94.8%) .190
/40 (82.5%) 30/32 (93.8%) .952
follow-up time point.
Table 5. Impact of CD34+ Cell Dose on Platelet and RBC Transfusion
CD34+ Cell Dose, Cells/kg
NHL (3101 Study) 2-4  106 (n 5 76) 4-6  106 (n 5 75) >6  106 (n 5 66) P value*
Platelet transfusion
Number of patients who received transfusion (%) 74 (97.4) 75 (100.0) 62 (93.9) NS
Number of transfusions per patient
Mean ± SD 4.0 ± 3.0 3.7 ± 2.9 3.1 ± 3.0 0.03†
Median (range) 3 (0–17) 3 (1–19) 2 (0–18)
Number of units transfused per patient
Mean ± SD 6.2 ± 7.6 7.8 ± 8.9 7.1 ± 12.8 NS
Median (range) 4 (1–42) 4 (1–40) 3 (1–95)
RBC transfusion
Number of patients who received transfusion (%) 72 (94.7) 61 (81.3) 52 (78.8) .006
Number of transfusions per patient
Mean ± SD 2.0 ± 1.9 1.8 ± 1.3 1.5 ± 1.2 NS
Median (range) 2 (0–12) 2 (0–6) 1 (0–6)
Number of units transfused per patient
Mean ± SD 3.6 ± 3.6 3.6 ± 1.9 3.2 ± 1.7 NS
Median (range) 3 (1–26) 3 (1–11) 2 (1–10)
MM (3102 study)
CD34+ Cell Dose, Cells/kg
2-4  106 (n 5 75) 4-6  106 (n 5 82) >6  106 (n 5 64) P value*
Platelet transfusion
Number of patients who received transfusion (%) 66 (88.0) 68 (82.9) 51 (79.7) NS
Number of transfusions per patient
Mean ± SD 2.2 ± 2.3 1.6 ± 1.4 1.6 ± 1.9 NS
Median (range) 1 (0–10) 1 (0–7) 1 (0–11)
Number of units transfused per patient
Mean ± SD 5.4 ± 9.9 4.0 ± 5.5 5.7 ± 9.9 NS
Median (range) 2 (1–64) 2 (1–37) 2 (1–55)
RBC transfusion
Number of patients who received transfusion (%) 52 (69.3) 53 (64.6) 34 (53.1) .052
Number of transfusions per patient
Mean ± SD 1.3 ± 1.5 1.1 ± 1.2 1.0 ± 1.2 NS
Median (range) 1 (0–7) 1 (0–7) 1 (0–5)
Number of units transfused per patient
Mean ± SD 3.4 ± 2.9 2.6 ± 1.8 3.2 ± 1.7 NS
Median (range) 2 (1–16) 2 (1–13) 2.7 (1–10)
MM indicates multiple myeloma; NHL, non-Hodgkin lymphoma; NS, not significant; RBC, red blood cell; SD, standard deviation.
*P value testing linear trend using Mantel-Haenszel chi-square test (for dichotomous outcomes) orWilcoxon rank sum test (for continuous outcomes).
†Significant difference only between the 2-4  106 cells/kg and >6  106 cells/kg cell dose categories.
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It is generally accepted that the minimum number
of CD341 cells required for ASCT is 2  106 cells/kg
and the optimum number is $5  106 cells/kg. Previ-
ous studies have demonstrated that a higher number of
transplanted CD341 cells is correlated with faster he-
matopoietic recovery, particularly platelet recovery,
longer survival, and reduced cost of care [14-22],
justifying the need to collect the optimum number of
CD341 cells, regardless of the number of aphereses
it takes to obtain these. The analyses presented here
are based on 2 large, randomized, phase 3 trials
(Studies 3101 and 3102) that compared plerixafor
plus G-CSF versus placebo plus G-CSF as the
mobilization regimen in patients with NHL or MM
[28,29]. We found that following transplantation, the
median times to short-term platelet and neutrophil en-
graftment were similar regardless of CD341 cell dose.
The trends reported for the delay in platelet engraft-
ment in patients receiving fewer CD341 cells/kg may
be biased by the small number of patients included inprior studies, as well as the much broader range of
CD341 counts (\1 to .10  106 cells/kg) evaluated
in prior studies [14,16].
In a retrospective study of thrombopoiesis in 359
patients undergoing autologous transplantation, the
achievement of a platelet count of $150  109/L by
100 days posttransplant (or initial engraftment) was in-
dependently associated with a significantly higher
number of transplanted CD341 cells/kg and improved
posttransplant survival [31]. Similar to these previous
findings, we observed a significant linear association
between CD341 cell dose and percentage of patients
with a platelet threshold of 150  109/L at 100 days
for both NHL and MM and at 6 and 12 months for
NHL patients. These patients also experienced
a need for fewer platelet transfusions (at a cell dose
of .6  106 cells/kg) and a lower percentage of pa-
tients with NHL receiving RBC transfusions. These
results are in agreement with the findings of previous
studies that show a positive impact of higher trans-
planted cell doses on faster platelet recovery [16-18]
and decreased transfusion requirements [16,21,22].
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number on the recovery of other blood cells (lympho-
cytes, neutrophil, and RBCs). These results are some-
what inconsistent with previously published data,
which showed a positive correlation between CD341
cell number and recovery of lymphocytes, neutrophils,
and RBCs [14-16,21,22]. The reasons for the
discrepancy are unknown and may be related to the
differences in mobilization regimens, patient
population, study design, and sample size. Prior
correlative studies utilized growth factor (G-CSF or
granulocyte-macrophage colony stimulating factor
[GM-CSF]) alone, chemotherapy alone, or a combina-
tion of growth factor with chemotherapy in their mo-
bilization regimens [14-16,21,22]. With a cutoff of
approximately 5  106 CD341 cells/kg, median time
to recovery of neutrophils [16,21,22] platelets
[16,21,22], and leukocytes [21] was significantly im-
proved in patients receiving $5  106 CD341 cells/
kg. Duggan and colleagues [14] showed that following
G-CSF and chemotherapy mobilization, CD341 cell
dose (1-5, 5-10, 10-16, and .16  106 CD341 cells/
kg) was significantly and inversely correlated with the
percentage of patients with low neutrophil and platelet
(but not RBC) recovery.
We did observe a significant impact of cell dose on
the number of platelet transfusions as well as on the
proportion of patients requiring RBC transfusions.
In patients with NHL (Study 3101), there was a signif-
icantly lower median number of platelet transfusions
in the 6  106 CD341 cells/kg cell dose group com-
pared with the 2-4  106 CD341 cells/kg group, as
well as a lower percentage of patients who received
RBC transfusions with increasing cell doses.
Prior studies of patients infused with $5  106
CD341 cells/kg showed fewer platelet [21,22] or
RBC [22] transfusions compared with patients infused
with\5  106 CD341 cells/kg, and consequently sig-
nificantly reduced resource utilization [22]. Sola et al.
[16] showed an inverse correlation between the num-
ber of mobilized CD341 cells (by cyclophosphamide
and G-CSF) and the number of platelet transfusions.
We did not observe any significant differences in 1-
year posttransplantation survival across cell dose cate-
gories. In addition, a separate survival analysis based
on mobilization regimen demonstrates that 1-year OS
estimates for patients in the plerixafor plus G-CSF ver-
sus placebo plus G-CSF groups were similar in both
Study 3101 and 3102 [32]. Given the low death rate at
1 year, longer follow-up periods may be warranted to
detect a significant difference. Given the fact that 1-
year survival rates areusually high in thesepatients, it re-
mains possible that any cell dose above the 2 106 cells/
kg threshold will achieve similar survival outcomes. To
date, as expected, posttransplantation myeloid malig-
nancies have been rare in our study, with only 1 case
of pre-existingMDS and 2 cases of AML, all in patientswithNHL, although thiswill bearwatching because the
median time to develop these posttransplantation com-
plications is much longer and there has been relatively
short follow-up to date. A long-term monitoring study
of these populations is ongoing. Indeed, this large data
set may ultimately help clarify the importance of
CD34 dose on the development of these complications.
Collective evidence in a 2000 review by Siena and
colleagues [15] provides support for the clinical rele-
vance of CD341 cell dose in transplantation. The
recommended CD341 cell dose for ASCT was $5 
106 cells/kg (minimum 2 106 cells/kg; optimal$8
106 cells/kg to achieve 100% engraftment) and has
been considered a key factor in hematopoietic recovery
and satisfactory engraftment.This guidancehas proven
reliable in providing consistent results in studies where
G-CSF was the standard treatment for mobilizing
CD341 cells. Studies 3101 and 3102 have established
the role of plerixafor as part of stem cell mobilization
regimen that improves the success rate of stem cell
collection. Our analyses are based on cell dose cate-
gories, regardless of mobilization regimen (plerixafor
plus G-CSF versus placebo plus G-CSF). Taken to-
gether, these data suggest that the recent incorporation
of plerixafor as part of the mobilization regimen con-
tributes to improving the chance of transplanting
a higher number of CD341 cells (which in turn, corre-
lates with better platelet recovery) without negatively
impacting graft durability or patient survival.ACKNOWLEDGMENTS
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